Business Wire

Western Union Foundation Announces New Partnerships to Advance Vaccine Education & Workforce Training in Q1/2021

Share

The Western Union Foundation today announced its first-quarter 2021 programs, investing more than USD 1.25 million to mobilize youth to access jobs in the healthcare industry, assisting with COVID-19 vaccine education and distribution, and to enable economic recovery through workforce training. This investment furthers the Western Union Foundation’s Opportunity Beyond Borders three-year USD 15 million commitment to provide migrant and young adults with resources to gain sustainable employment and provide relief and preparedness for crises.

“The Western Union Foundation recognizes that this moment—as the global pandemic recovery effort begins in earnest—is a crucial one for the communities we serve,” said Foundation Executive Director Elizabeth Roscoe. “We are determined to do everything we can to keep people who are already on the margins from falling farther behind because they lack access to vaccines or opportunities to participate in the formal labor markets as economies progress toward recovery.”

In 2020, the first full year of Opportunity Beyond Borders, the Western Union Foundation invested more than USD 6 million to help 200,000 people in 33 countries, as detailed in its 2020 Global Impact Report.

COVID-19 vaccine education, preparedness, and distribution programs

Research has shown a large portion of the population in many low-income countries is hesitant to get the vaccine, often due to lack of education about the vaccine and logistical challenges to reach vaccine centers. The Aspen Institute and International Medical Corps will receive funds from the Western Union Foundation to address these challenges.

In Kenya and India, the Aspen Institute will partner with leading community-based organizations to support vaccine education and distribution efforts by skilling youth and women in the community in vaccine awareness, preparedness and access.

In the Philippines, the International Medical Corps program will address vaccine hesitancy by driving awareness and coordinating transportation for vulnerable populations to vaccine centers.

In Pakistan, host to the third-largest number of refugees in the world, International Medical Corps will train volunteers in refugee villages to raise vaccine awareness and promote health and hygiene best practices.

Western Union and the Foundation are further enabling vaccine adoption by donating funds on behalf of each vaccinated Western Union employee and allowing employees to donate directly to the cause. This program will provide up to $350K to help inoculate thousands more in rural communities.

Workforce training for entrepreneurship and career pathways

In addition to the COVID-19 community resilience programs, the Foundation’s first-quarter investment aims to enable economic recovery for migrant and refugee communities affected by last year’s lockdowns. The following are a few of the programs:

In Mexico, the Whitaker Peace & Development Initiative will scale entrepreneurship programs by training young business leaders and incubating micro-businesses that provide essential services and products to their local communities.

In Jordan and Lebanon, the Kiron Open Higher Education program will work with the most vulnerable populations residing in refugee encampments and will offer skill-building opportunities to prepare individuals for and give access to career pathways.

In Jordan and Palestine, Education for Employment will launch a research study about relevant jobs post-COVID-19 and provide customized training to business owners, with the majority female, helping them adapt and grow their businesses in response to the effects of COVID-19.

To learn more about the impact the Western Union Foundation has made to people and partners over the past year, check out the stories of impact on their newly launched website.

About the Western Union Foundation

The Western Union Foundation believes that education is the surest pathway to economic opportunity. After 20 years of impact, we continue to deliver on our mission with Opportunity Beyond Borders, focused on empowering forcibly displaced and marginalized youth with the training and education needed to succeed in today’s technology-driven global economy. The Foundation also provides funding for humanitarian efforts for communities in crisis and disaster, one key reason for forced migration. To date, we have funded more than $131 million for projects and scholarships. The Western Union Foundation is a separate, tax-exempt 501(c)(3) charitable corporation and receives support from The Western Union Company, its employees, agents, and business partners. Contributions to the Foundation are tax-deductible for U.S. income tax purposes. To learn more, visit www.westernunionfoundation.org or follow us on Twitter @TheWUFoundation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:
Western Union Global Communications; Pia De Lima; Pia.DeLima@wu.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye